All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1500+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Clinical Trials

AstraZeneca, Daaichi-Sankyo showcases subgroup overall survival data from Ph2 and Ph3 trial of datopotamab deruxtecan (targeting TROP2) in lung cancer
Antibody-drug conjugate, lung cancer - Read more

Duality Biologics, BioNTech touts positive Ph1/2a interim data for BNT324/DB-1311 (targeting B7-H3) in lung and prostate cancer
Antibody-drug conjugate, lung cancer, prostate cancer - Read more

Medicenna touts updated Ph1/2 data for MDNA11 (targeting IL-2) combined with Keytruda (Merck & Co.) in various solid tumors
Biologic, anal cancer, melanoma, colorectal cancer - Read more

Nektar Therapeutics touts “enhanced” complete response rates in Ph2 trial of CAR-T therapy adjuvant NKTR-255 (IL-15 receptor agonist)
Biologic, lymphoma, IL-15 polymer conjugate, cancer - Read more

Galapagos touts “encouraging” new data from Ph1/2 GLPG5101 (targeting CD19) cell therapy in non-Hodgkin lymphoma
Cell therapy, lymphoma, cancer, CAR-T - Read more

Arcellx shares updated Ph2 results for Gilead-partnered anito-cel (targeting BCMA) in multiple myeloma
Cell therapy, multiple myeloma, cancer, CAR-T - Read more

PRESENTED BY YOU?
Get the attention of 1500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

⬇️ More Good News ⬇️

THE GOOD
Clinical Trials (continued)

Beacon Therapeutics’ laru-zova gene therapy Ph2 trial delivers positive 3 month data in X-linked retinitis pigmentosa
Gene therapy, X-linked retinitis pigmentosa - Read more

bluebird bio touts positive long-term Lyfgenia gene therapy data in sickle cell disease
Gene therapy, sickle cell disease - Read more

Beam Therapeutics touts positive preliminary Ph1/2 data in BEAM-101 gene editing therapy in sickle cell disease
Genetically modified cell therapy, sickle cell disease, gene editing - Read more

AstraZeneca posts positive Ph3 data for Calquence (BTK inhibitor) in chronic lymphocytic leukaemia
Small molecule, chronic lymphocytic leukaemia - Read more

Novartis touts new Ph3b data for Fabhalta (Factor B inhibitor) in improving hemoglobins levels in patients with paroxysmal nocturnal hemoglobinuria
Small molecule, paroxysmal nocturnal hemoglobinuria - Read more

Pharma Two B’s pooled Ph2b, Ph3 analysis for P2B001 (pramipexole and rasagiline) in early-stage Parkinson’s disease
Small molecule, Parkinson’s disease - Read more

Medicinova’s interim Ph2/3 analysis of ibudilast (phosphodiesterase inhibitor, toll-like receptor 4 antagonist) in ALS
Small molecule, amyotrophic lateral sclerosis - Read more

THE GOOD
Investments

Moderna opens mRNA vaccine manufacturing site in Victoria, Australia
mRNA, vaccine, manufacturing, infectious disease - Read more

THE GOOD
Lawsuits

MSN Pharmaceuticals’ Entresto generic continues on as Novartis’ blocking attempt shot down by appeals court
Small molecule, heart failure, generic - Read more

THE GOOD
Mergers & Acquisitions

Novo Holdings’ Catalent acquisition given the OK by EU regulators
CDMO, contract manufacturing - Read more

Both Teva Pharmaceuticals & Takeda to divest their generics and off-patent medicines joint venture Teva Takeda Pharma to PE firm J-Will Partners
Small molecule, generics, off-patent medicines - Read more

THE GOOD
Partnerships

Aclarais Therapeutics, Sino Biopharm, Biosion enter global collaboration for developing BSI-045B (anti-TSLP)
Monoclonal antibody, autoimmune - Read more

Indapta Therapeutics, Sanofi clinical trial collab targeting multiple myeloma; allogeneic g-NK cell therapy + sarclisa (targeting CD38)
Cell therapy, multiple myeloma, monoclonal antibody, cancer, g-NK cell - Read more

THE GOOD
Politics & Policy

Biosecure hits roadblocks as legislation left out of defence spending bill
Biosecure Act, federal funding, outsourcing - Read more

Pfizer, Eli Lilly CEOs and lobby group PhRMA head were likely all charisma at dinner with President-elect Trump
Pharma industry, industry policy - Read more

THE GOOD
Public Health

USDA imposes mandatory H5N1 testing in cow milk
Infectious disease, H5N1 (bird flu) - Read more [Paywall]

THE GOOD
Strategic Plans

Novo Nordisk to slash insulin prices come 2026
Insulin, drug pricing, diabetes - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Clinical Trials

BioAge Labs shutters Ph2 azelaprag (apelin receptor agonist) trial after increased liver enzymes detected
Small molecule, obesity - Read more

THE BAD
Layoffs

National Resilience to layoff 105 employees at Florida site
CDMO, manufacturing - Read more [Paywall]

AmplifyBio shutters South San Francisco R&D, characterization site and announces layoffs for Ohio preclinical CRO division
CMDO, CRO, contract manufacturing, contract research - Read more

THE BAD
Public Health

UK’s pandemic preparedness not adequate according to government committee, “worrying developments” in domestic vaccine manufacturing capacity
Pandemic preparedness, vaccine manufacturing, infectious disease - Read more [Paywall]

THE BAD
Strategic Plans

Cyclacel in the dreaded “strategic alternatives” phase as cash pile dwindles
Small molecule, lymphoma, solid tumor, cancer - Read more

THE UGLY
No Ugly Stories today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here